Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
SpaceX launches Starlink satellites from California on 160th Falcon 9 flight of the year (video) - 2The most effective method to Pick the Ideal Lab Precious stone Wedding band
- 33 astronauts settle into their new life in orbit | On the International Space Station this week Dec. 1-5, 2025
- 4Vote In favor of Your Favored Menial helper Administration
- 5Manual for 6 Hot Brilliant Beds
- Women take pride in Holy Week roles after a Spanish Catholic brotherhood's procession excluded them
- German mid-sized firms gloomy on outlook, survey finds
- The Fate of Rest: Patterns in Shrewd Beds
- Surprise! Saturn's huge moon Titan may not have a buried ocean after all
- Vote In favor of Your #1 Method for diminishing Pressure
- Opening Innovativeness: Moving Thoughts and Tasks
- Scientists solve the mystery of 'impossible' merger of 'forbidden' black holes
- The most effective method to Perceive the Early Side effects of Cellular breakdown in the lungs
- Which camera do you believe is great for first-time clients? !
